1. 23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064). (September 2015) Authors: Hodi, F.S.; Gibney, G.; Sullivan, R.; Sosman, J.A.; Slingluff, C.L.; Lawrence, D.P.; Logan, T.F.; Schuchter, L.M.; Nair, S.; Fecher, L.; Buchbinder, E.; Ruisi, M.; Kong, G.; Horak, C.; Weber, J.S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma. (September 2015) Authors: Long, G.V.; Dummer, R.; Ribas, A.; Puzanov, I.; Michielin, O.; Vanderwalde, A.; Andtbacka, R.H.I.; Cebon, J.; Fernandez, E.; Malvehy, J.; Olszanski, A.J.; Gajewski, T.F.; Kirkwood, J.M.; Gause, C.; Chen, L.; Kaufman, D.R.; Chou, J.; Hodi, F.S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S722 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067). (September 2015) Authors: Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Wagstaff, J.; Hogg, D.; Hill, A.; Carlino, M.S.; Wolter, P.; Lebbé, C.; Schachter, J.; Thomas, L.; Hassel, J.C.; Lorigan, P.; Walker, D.; Jiang, J.; Hodi, F.S.; Wolchok, J.D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S664 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study. (September 2015) Authors: Giaccone, G.; Camidge, D.R.; Liu, S.V.; Powderly, J.; Hodi, F.S.; Gettinger, S.N.; Heist, R.S.; Liu, B.; Wallin, J.; Funke, R.; Waterkamp, D.; Ready, N.E. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. Issue 9 (November 2017) Authors: Gangadhar, Tara C.; Hwu, Wen-Jen; Postow, Michael A.; Hamid, Omid; Daud, Adil; Dronca, Roxana; Joseph, Richard; O'Day, Steven J.; Hodi, F.S.; Pavlick, Anna C.; Kluger, Harriet; Oxborough, Romina P.; Yang, Aiming; Gazdoiu, Mihaela; Kush, Debra A.; Ebbinghaus, Scot; Salama, April K.S. Journal: Journal of immunotherapy Issue: Volume 40:Issue 9(2017:Nov./Dec.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies. (February 2017) Authors: Butler, M.; Hamid, O.; Ribas, A.; Hodi, F.S.; Walpole, E.; Dauad, A.; Arance, A.; Brown, E.; Hoeller, C.; Mortier, L.; Schachter, J.; Long, J.; Ebbinghaus, S.; Ibrahim, N.; Robert, C. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma. (July 2015) Authors: Ribas, A.; Wolchok, J.D.; Robert, C.; Kefford, R.; Hamid, O.; Daud, A.; Hwu, W-J.; Weber, J.S.; Joshua, A.M.; Gangadhar, T.C.; Patnaik, A.; Hersey, P.; Dronca, R.; Zarour, H.; Gergich, K.; Lindia, J.A.; Giannotti, M.; Li, X.N.; Ebbinghaus, S.; Kang, S.P. Journal: European journal of cancer Issue: Volume 51(2015)Supplement 2 Page Start: e24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗